S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:PAVM

PAVmed Stock Forecast, Price & News

$5.72
-0.45 (-7.29 %)
(As of 10/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.68
$6.10
50-Day Range
$5.83
$9.39
52-Week Range
$1.63
$9.70
Volume4.64 million shs
Average Volume3.04 million shs
Market Capitalization$484.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.31
30 days | 90 days | 365 days | Advanced Chart
Receive PAVM News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.


PAVmed logo

About PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy, and Emerging Innovations. The GI health division comprises of EsoGuard esophageal DNA laboratory developed test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus technology. The minimally invasive interventions division offers CarpX minimally invasive surgical device for carpal tunnel syndrome. The infusion therapy division includes PortIO implantable intraosseous vascular accedd device and NextFlo highly accurate disposable intravenous infusion platform technology. The emerging innovations divisions consists of non-invasive laser-based glucose monitoring, single-use ventilators, resorbable pediatric ear tubes and mechanical circulatory cannulas. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PAVM
Employees
25
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($0.04) per share

Profitability

Net Income
$-34.28 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$484.87 million
Next Earnings Date
11/16/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

328th out of 1,359 stocks

Surgical & Medical Instruments Industry

34th out of 124 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












PAVmed (NASDAQ:PAVM) Frequently Asked Questions

Is PAVmed a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PAVmed stock.
View analyst ratings for PAVmed
or view top-rated stocks.

What stocks does MarketBeat like better than PAVmed?

Wall Street analysts have given PAVmed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PAVmed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is PAVmed's next earnings date?

PAVmed is scheduled to release its next quarterly earnings announcement on Tuesday, November 16th 2021.
View our earnings forecast for PAVmed
.

How were PAVmed's earnings last quarter?

PAVmed Inc. (NASDAQ:PAVM) posted its quarterly earnings data on Thursday, August, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04.
View PAVmed's earnings history
.

How has PAVmed's stock price been impacted by Coronavirus?

PAVmed's stock was trading at $1.74 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PAVM shares have increased by 228.7% and is now trading at $5.72.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PAVM?

4 brokers have issued twelve-month target prices for PAVmed's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate PAVmed's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 31.1% from the stock's current price.
View analysts' price targets for PAVmed
or view top-rated stocks among Wall Street analysts.

Who are PAVmed's key executives?

PAVmed's management team includes the following people:
  • Lishan Aklog, Chairman & Chief Executive Officer
  • Dennis M. McGrath, President, Chief Financial Officer & Secretary
  • Brian J. deGuzman, Chief Medical Officer
  • Shaun M. O’Neil, Chief Commercial Officer
  • James Mitchell, Vice President-Digital Health

What other stocks do shareholders of PAVmed own?

What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

Who are PAVmed's major shareholders?

PAVmed's stock is owned by a variety of institutional and retail investors. Top institutional investors include RFG Advisory LLC (0.21%), Vigilare Wealth Management (0.08%), Total Clarity Wealth Management Inc. (0.04%), Private Advisor Group LLC (0.03%) and FNY Investment Advisers LLC (0.01%). Company insiders that own PAVmed stock include Lishan Aklog, Matthew Sirovich and Pavmed Inc.
View institutional ownership trends for PAVmed
.

Which major investors are selling PAVmed stock?

PAVM stock was sold by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.
View insider buying and selling activity for PAVmed
or view top insider-selling stocks.

Which major investors are buying PAVmed stock?

PAVM stock was bought by a variety of institutional investors in the last quarter, including RFG Advisory LLC, Total Clarity Wealth Management Inc., Private Advisor Group LLC, and FNY Investment Advisers LLC. Company insiders that have bought PAVmed stock in the last two years include Lishan Aklog, and Pavmed Inc.
View insider buying and selling activity for PAVmed
or or view top insider-buying stocks.

How do I buy shares of PAVmed?

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PAVmed's stock price today?

One share of PAVM stock can currently be purchased for approximately $5.72.

How much money does PAVmed make?

PAVmed has a market capitalization of $484.87 million. The company earns $-34.28 million in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does PAVmed have?

PAVmed employs 25 workers across the globe.

What is PAVmed's official website?

The official website for PAVmed is www.pavmed.com.

Where are PAVmed's headquarters?

How can I contact PAVmed?

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at (212) 949-4319 or via email at [email protected].


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.